Rifaximin
Kathryn Dzintars, Pharm.D., BCPS
,
Paul A. Pham, Pharm.D.
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Treatment of
traveler’s diarrhea
due to noninvasive
E. coli
Reduction in risk of overt hepatic encephalopathy recurrence
Treatment of Irritable Bowel Syndrome-diarrhea predominant (IBS-D)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
NON-FDA APPROVED USES
C. difficile
-
associated diarrhea (prevention, or second-line treatment)
Small bowel bacterial overgrowth
Prevention of
traveler’s diarrhea
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved